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Acute myocardial infarction (AMI) in pregnancy is associated with high morbidity and
mortality. Management of these patients can be challenging as little is known about the
optimal management strategy. Medications routinely used may have harmful effects on
the pregnancy outcome. In addition, AMI could occur in the absence of atherosclerotic
disease. We describe optimal management strategy by eliciting the management of a 45-
year-old female with ST segment elevation myocardial infarction. We recommend early
use of coronary angiography to define the pathology in such cases. Radial artery assess
should be preferred. Pregnant patients with AMI due to atherosclerotic disease should be
given a 325 mg of aspirin and 600 mg of clopidogrel and either balloon angioplasty or bare
metal stent should be used for revascularization. Percutaneous coronary intervention with
heparin is preferred over bivalirudin and later should be reserved for patients with severe
heparin allergy.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction United KingdomObstetric Surveillance System (UKOSS) studyThe prevalence of coronary artery disease (CAD) in women
increases with age.1 There is a trend toward women getting
pregnant at an older age,2 which could be attributed to late
marriages, improvements in infertility management, life style
choices and professional demands. This may result in
increased chance of witnessing more pregnant women with
acute myocardial infarction (AMI) in near future. To that end,
pregnancy itself increases the risk of AMI three to fourfold.3
Also, preeclampsia4 and gestational diabetes mellitus (DM)5
during earlier pregnancies increases the risk of future
ischemic heart disease.
Accurate burden cannot be predicted due to lack of sys-
temic studies and national or international registries. Thelar Center, 5645 Main Str
m, abhishek_jais@hotma
2013, Cardiological Socieestimated the incidence of AMI during pregnancy at 0.7 per
100,000 maternities (0.4e1.0 95% CI).6 The overall incidence
has been estimated to be around 1 case per 10,000e24,000
deliveries.7 Usually multiparas and women with underlying
traditional risk factors for cardiovascular diseases are at
higher risk. Atherosclerotic disease remains the primary
cause of AMI during pregnancy in patients presenting at
antepartum period and coronary artery dissection accounts
for almost 50% of the cases during peripartum period.8
Fortunately, the outcome of AMI in pregnancy is improved
significantly with decrease in case fatality rate from 30% to
5e10% and fetal fatality from 17% to 9%.7 Most of maternal
fatality happens at the time of infarction or within 2 weeks
during labor and delivery.8 Fetal deaths occur due toeet, Flushing, New York 11365, USA. Tel.: þ1 718 661 7204; fax: þ1
il.com (A. Jaiswal).
ty of India. All rights reserved.
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termination of pregnancy. The low incidence, atypical pre-
sentation and difficult pathophysiology of maternalefetal
circulation create a complex clinical scenario. Some of the key
questions which remain to be answered are the role of routine
coronary angiography, strategies to minimize fetal radiation
exposure, optimal antithrombotic and antiplatelet regimen to
avoid peripartum bleeding and adverse fetal outcome, revas-
cularization strategy to maximize the benefit without
increasing side effects of long-term antiplatelet therapy, and
safe drugs during lactation.2. Case report
A 45-year-old Guyanese female of Indian origin in her twenty-
fifth-week of pregnancy presented to the emergency depart-
ment with acute onset progressive chest pain and diapho-
resis. She did not have any documented cardiovascular risk
factors and denied any complications during prior normal
vaginal pregnancy 15 years ago. She was taking her multivi-
tamin pills and no other prescribed medications. Her parents
and sibling did not have CAD and DM.
Initial assessment revealed an afebrile pregnant lady with
blood pressure e 117/79 mmHg, pulse e 89 beats per minute,
pulse oximetry e 99% on room air. There were no signs of
congestive heart failure with clear lungs and no jugular
venous distension. The precordial auscultation revealed
normal sounds with physiological splitting. Electrocardiog-
raphy (EKG) showed ST segment elevation in anterolateral
leads V1eV4, I and aVL with reciprocal ST depressions in
inferior leads II, III and aVF (Fig. 1). Coronary catheterization
was performed through right radial artery access after
shielding the patient’s back and abdomen with lead aprons
to minimize fetal radiation exposure. Angiogram showed
(Fig. 2) total occlusion of the proximal left anterior
descending (LAD) artery with normal right and left circum-
flex coronary arteries. Left ventricular systolic function was
reduced to 45% with severely hypokinetic mid to distal
anterior wall. Patient received 325 mg aspirin and loadingFig. 1 e EKG showing ST elevation in precordial leads V1eV4, la
leads II, III and aVF.dose of (600 mg) clopidogrel. Mechanical thrombectomy was
performed, and a bare metal stent was deployed in the LAD
(Fig. 2). Intra-arterial heparin was used to maintain anti-
coagulation during coronary intervention. Total fluoroscopy
time was 06 min and 42 s. During procedure she complained
of increasing shortness of breath and pink frothy sputum
production with decreased saturation on pulse oximetry. She
improved after receiving diuretics and non-invasive venti-
latory support through bilevel positive airway pressure
(BiPAP). Post angioplasty EKG showed resolution of ST seg-
ments (Fig. 3). She had an uncomplicated hospital course.
Pre-discharge transthoracic echocardiography revealed
normal left ventricular function without any wall motion
abnormality. She was discharged on 81 mg aspirin, 75 mg
clopidogrel, 25 mg metoprolol tartrate twice a day regimen.
She delivered on due date at 38 weeks period of gestation
without any complication, and underwent cesarean section
for labor arrest. Antiplatelet regimen was not interrupted
during labor and delivery in our patient. She remained
asymptomatic during follow up with optimal medical man-
agement. Lovastatin was added to her regimen 6 months
after pregnancy.3. Discussion
Pertinent issues that are germane for timely diagnosis and
effective management of AMI in pregnancy include the
following: role of routine coronary angiography, strategies to
minimize fetal radiation exposure, optimal antithrombotic
and antiplatelet regimen to avoid peripartum bleeding and
adverse fetal outcome, revascularization strategy tomaximize
benefits, and safe drugs during lactation.
Diagnostic evaluation includes clinical history, EKG
changes in conjunction with cardiac biomarkers. Interpreta-
tion of biomarkers can be difficult as levels are influenced by
pregnancy, labor and delivery. This is due to release of en-
zymes from the uterus and placenta, which embody sub-
stantial amounts of these enzymes.9 A definitive diagnosis
can only be made after coronary angiography.teral leads I, aVL with reciprocal ST depression in inferior
Fig. 2 e Right Anterior Oblique view with caudal rotation showing complete occlusion of proximal left anterior descending
coronary artery (Panel A) and post stent deployment angiogram showing re establishment of blood flow across left anterior
descending coronary artery with guidewire in distal segment (Panel B).
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Federal Drug Administration (FDA) has categorized drugs
based on pregnancy risk categories and selection should be
done in conjunction with the recommendations. High dose
aspirin (ASA) is associated with fetal hemorrhage, perinatal
mortality, intrauterine growth restriction and teratogenic ef-
fects.10 Low dose ASA is safe in pregnancy during second and
third trimesters.7 ASA is secreted in breast milk in low con-
centrations without any adverse effect. Heparin (unfractio-
nated heparin category C, low-molecular weight heparin
(LMWH) category B) use is safe in pregnancy. It is recom-
mended to stop a day prior to delivery and monitor anti-Xa
levels if LMWH is used.11 At the time of coronary interven-
tion, heparin should be dosed to target an activated clotting
time of at least 200 s, but not exceeding 300 s.12 During spon-
taneous labor, protamine sulfate might be required to reduce
the risk of bleeding, and to allow safe local and epidural
anesthesia. Bivalirudin (Category B), a parental direct
thrombin inhibitor, shouldbe limited to thosewhohave severeFig. 3 e Subsequent EKG showinallergic reactions to heparin, including heparin-induced
thrombocytopenia, and who cannot receive danaparoid.13
Thienopyridines (Ticlopidine, Clopidogrel, Prasugrel and
Ticagrelor) have limited data in pregnancy. There are only a
handful of case reports, which used dual antiplatelet agents
using ASA and Clopidogrel (category B) during pregnancy. It is
desired that Clopidogrel be stopped a week prior to any
regional anesthesia procedures. Ticagrelor is only recom-
mended for use during pregnancy when there are no alter-
natives and benefit outweighs risk. Excretion into human
breast milk is unknown; use is not recommended.
Glycoprotein IIb/IIIa inhibitors, e.g. Eptifibatide, Tirofiban
andAbciximab,havenotbeen studied inpregnant patients and
randomized trials excluded pregnant patients. FDA has
assigned pregnancy risk Category B to Eptifibatide and Tir-
ofiban;andcategoryCtoAbciximab.Thesedrugsshouldbebest
avoided inpregnantpatients,however, if theseagentsareused,
a cesarean section is recommended to decrease the potential
for fetal intracranial hemorrhage during vaginal delivery.
Angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin receptor blockers (ARB) (category C) areg resolution of ST segments.
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excreted in breast milk and thus breastfeeding should be dis-
continued in patients requiring ACEI/ARB. Hydralazine with or
without nitrates is generally the vasodilator of choice during
pregnancy.14 Statins are contraindicated during pregnancy. In
patients developing heart failure, Furosemide (category C) and
Hydrochlorothiazide (HCTZ) (category B) have been safely uti-
lized during pregnancy.14 Spironolactone (category C) should
better be avoided during the antepartum period.15 Despite no
evidence of teratogenic effects, Morphine (category C) should
be avoided during pregnancy for the risk of fetal respiratory
compromise and neonatal respiratory depression.
4.1. Thrombolytics vs coronary angiography
Thrombolytics should be avoided during AMI in pregnancy
without knowledge of coronary anatomy, as itmay potentially
complicate coronary dissection cases by increasing the risk of
hemorrhage and further progression of the dissection.7 Cor-
onary angiography is underutilized for this patient population
due to radiation safety concerns. This not only helps in
differentiating coronary spasm and coronary artery dissection
from atherosclerotic disease but also provides a therapeutic
tool. The amount of fetal exposure to radiation during coro-
nary intervention is estimated to be between 0.02 and
0.1 mSv.16 These radiation exposures are well below the
threshold for teratogenicity at any gestational age.16 Radiation
can be further reduced by the use of appropriate protection
shields. Covering patient’s abdomen and back by lead might
protect the fetus from excessive radiation. Radial artery
approach has logistic advantage over femoral artery access in
these cases, as it minimizes abdominal/fetal radiation. The
concern overmore radiation exposure due tomore fluoro time
required to perform coronary intervention utilizing radial
approach is theoretical, operator dependant and has been
recently challenged by Kuipers et al.17 Bare metal stents (BMS)
still remain preferred choice over drug eluting stents (DES) in
these patients. DES is generally avoided due to necessary long-
term need for dual antiplatelet therapy with Aspirin and
Clopidogrel. The duration of dual antiplatelet therapy after
stent placement when the pregnancy continues and results in
labor and delivery is not well established. We recommended
continuation of Aspirin and Clopidogrel for at least 4 weeks
(for bare metal stents) unless there is a bleeding complication.
In patients developing ventricular tachycardia without
spontaneous resolution, Lidocaine is considered safe at clini-
cally recommended doses.18 Amiodarone is associated with a
significant incidence of fetal hypothyroidism (9% of newborns
of mothers on chronic amiodarone therapy), hyperthyroid-
ism, and goiter. Although Amiodarone is effective in virtually
all maternal and fetal tachycardias, its use is recommended
only in life-threatening cases where other therapies have
failed due to high incidence of serious adverse effects. Its use
during lactation is discouraged.18 Emergency and elective
cardioversion are safe at all stages of pregnancy.
4.2. Labor and delivery
Due to the increased hemodynamic stress associated with
labor, it has been recommended that induction of labor orscheduled cesarean delivery should be delayed, if possible, for
at least two to three weeks afterward.7 The mode of delivery
after AMI should be individualized based on clinical and ob-
stetric factors. In most cases, cesarean section is opted for
obstetric reasons. As discussed earlier, it should be preferred
in patients on Clopidogrel and patients with intractable heart
failure as well. Most patients with CAD can tolerate vaginal
delivery.7 Early continuous epidural anesthesia is recom-
mended to minimize pain, which can increase maternal heart
rate and myocardial oxygen demand. Episodes of tachycardia
and hypertension should be minimized. Ephedrine is usually
the vasopressor agent of choice for hypotension associated
with regional anesthesia because it helps maintain placental
perfusion.19 Ergot alkaloids immediately after delivery should
be avoided because of the risk of coronary artery spasm. Pa-
tient should be monitored for 48 h postpartum in a coronary
care unit as significant hemodynamic changes occur during
this time, whichwarrants closemonitoring and early action in
case of any instability.
CAD or prior myocardial infarction is not an absolute
contraindication to pregnancy and associated risk
depends on factors such as LVEF, active myocardial
ischemia, and the time between myocardial infarction and
planned pregnancy. Ideally, a pregnancy should be plan-
ned only a year after revascularization/myocardial
infarction.8 An ischemic evaluation should be pursued
preconception after patient is taken off the medications
that are contraindicated during pregnancy.5. Summary
Early use of coronary angiography is helpful in making a
diagnosis of coronary artery dissection, coronary spasm as
well as atherosclerotic disease. This information is crucial in
the management as medicines used to treat atherosclerotic
disease could potentially harm patients with coronary artery
dissection. Radial artery approach is associated with less ra-
diation exposure, better mobility and access site related
complications. After coronary angiogram, patients with AMI
due to atherosclerotic disease should be given a 325 mg of
aspirin and 600 mg of clopidogrel and either balloon angio-
plasty or bare metal stent should be used for revasculariza-
tion. Percutaneous coronary intervention with heparin is
preferred over bivalirudin and later should be reserved for
patients with severe heparin allergy. Statins should not be
used pending further studies.Conflicts of interest
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